Outcome and mortality analysis in complicated parapneumonic effusion and empyema
Background: Pleural infection is a clinical problem with high mortality and morbidity; 20% of patients with empyema die and approximately 20% require surgery to recover within 12 months of their infection. Studies on pleural infection and their outcome are relevant in developing a scoring system by which failing cases and cases at risk of death can be identified.
Methods: The study is retrospective analysis of patient cohort admitted to the tertiary care institute from the period of July 2014 to July 2016 to determine the prognostic factors in the outcome of pleural space infection. The study included all complex, complicated parapneumonic effusion and empyema including tuberculosis above the age of fifteen years. The primary end of the present study was the success or failure. Possible predicting factors for the success or failure of therapy were assessed against this end. Pearson chi square test, χ2 (Fisher’s exact test when needed) test was used for discrete data. Logistic regression analysis was applied to adjust for confounding variables to assess the possible predicting factors. Survival plot and analysis using Kaplan Meier method was used.
Results: 220 with parapneumonic effusion and empyema were analyzed. Successful outcome was seen in 107 and 113 had failed outcome. Mortality was 30.50%. By logistic regression method the odds of failed outcome were high with diabetes, hypoalbuminemia, loculation, tuberculosis which can predict the outcome especially complicated and complex parapneumonic effusion, empyema (p<0.05).
Conclusions: Diabetes, hypoalbuminemia, loculation, tuberculosis should be used in the prediction scoring system.
Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. Q J Med. 1996;89:285-9.
Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174:817-23.
Menendez R, Torres A, Zalacain R, Aspa J, Martín Villasclaras JJ, Borderías L, et al. Risk factors of treatment failure in community acquired pneumonia:implications for disease outcome. Thorax. 2004;59:960-5.
Hasley PB, Albaum MN, Li Y-H, Fuhrman CR, Britton CA, Marrie TJ, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med. 1996;156:2206-12.
Light RW, Girard WM, Jenkinson SG, George RB.. Parapneumonic effusions. Am J Med. 1980;69:507-11.
Taylor MD, Kozower BD. Surgical spectrum in the management of empyemas. Thorac Surg Clin. 2012;22:431-40.
Tsai CH, Lai YC, Chang SC, Chang CY, Wang WS, Yuan MK, et al. Video-assisted thoracoscopic surgical decortication in the elderly with thoracic empyema:five years’ experience. J Chin Med Assoc. 2016;79:25-8.
Ferreiro L, San Jose ME, Valdes L. Management of parapneumonic pleural effusion in adults. Arch Bronconeumol. 2015;51:637-46.
Strange C, Sahn SA. The definitions and epidemiology of pleural space infection. Semin Respir Infect. 1999;14:3-8.
Molnar TF. Current surgical treatment of thoracic empyema in adults. Eur J Cardiothoracic Surg. 2007;32:422-30.
Herrera-Kiengelher L, Baez-Saldana R, Salas-Hernandez J, Avalos-Bracho A, Pérez-Padilla R, Torre-Bouscoulet L. Frequency of adverse events and mortality in patients with pleural empyema in a public referral hospital in Mexico City. Int J Tuberc Lung Dis. 2010;14:1187-92.
Ashbaugh DG. Empyema thoracis. Factors influencing morbidity and mortality. Chest. 1991;99:1162-5.
Ahmed AE, Yacoub TE. Empyema thoracis. Clin Med Insights Circ Respir Pulm Med. 2010;4:1-8.
Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax. 2003;58:18-28.
Light RW, MacGregor Ml, Ball WC Jr, Luchsinger PC. Diagnostic significance of pleural fluid pH and Pco2. Chest. 1973;64:591-6.
Weese WC, Shindler ER, Smith IM. Empyema of the thorax then and now. Arch Intern Med. 1973;13:516-20.
Vianna NJ. Nontuberculous bacterial empyema in patients with and without underlying diseases. J Am Med Associat. 1971;215:69-75.
Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe. 2008;3(6):399–407.
Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis. 2008;47(5):634–41.
Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongekrijg J, Ottenhoff TH, van der Meer JW, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2008;27(2):97–103.
Banerjee D, Bhattacharyya R, Kaul D, Sharma P. Diabetes and tuberculosis: analysis of a paradox. Adv Clin Chem. 2011;53:139–53.
Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis. 2013;208(5):739–48.
Kourbatova EV, Leonard MK, Jr, Romero J, Kraft C, del Rio C, Blumberg HM. Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the U.S. Eur J Epidemiol. 2006;21(9):715–21.
Porkert MT, Sotir M, Parrott-Moore P, Blumberg HM. Tuberculous meningitis at a large inner-city medical center. Am J Med Sci. 1997;313(6):325–31.
Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, et al. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis. 2006;10(5):542–9.
LeMense GP, Strange C, Sahn SA. Empyema thoracic:therapeutic management and outcome. Chest. 1995;107:1532–7.
Pothula V, Krellenstein DJ. Early aggressive surgical management of parapneumonic empyemas. Chest. 1994;105:832-6.
Cham CW, Haq SM, Rahamim J. Empyema thoracis:a problem with late referral? Thorax 1993;48:925-7.
Chen KY, Liaw YS, Wang HC, Luh KT, Yang PC. Sonographic septation:a useful prognostic indicator of acute thoracic empyema. J Ultrasound Med. 2000;19:837-43.
Himelman RB, Callen PW. The prognostic value of loculations in parapneumonic pleural effusions. Chest. 1986;90:852-6.
Sahn SA. Management of complicated parapneumonic effusions. Am Rev Respir Dis. 1993;148:813-7.
Jimenez CD, Diaz G, Pérez-Rodríguez E, Light RW. Prognostic features of residual pleural thickening in parapneumonic pleural effusions. Eur Respir J. 2003;21:952-5.
Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007;45:1480–6.
Mandal AK, Thadepalli H. Treatment of spontaneous bacterial empyema thoracic. J Thorac Cardiovasc Surg. 1987;94:414–8.
Lemmer JH, Botham MJ, Orringer MB. Modern management of adult thoracic empyema. J Thorac Cardiovasc Surg. 1985;90:849–55.
Lee-Chiong TL Jr, Matthay RA. Current diagnostic methods and medical management of thoracic empyemas. Chest Surg Clin North Am. 1996;6:419–38.
Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. Am Rev Respir Dis. 1974;110:56–77.
Mavroudis C, Symmonds JB, Minagi H, et al. Improved survival in management of empyema thoracis. J Thorac Cardiovasc Surg 1981;82:49–57.
Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med. 1999;160(5):1682-7.